Merck & Co in advanced talks for acquisition season And according to people familiar with the matter, Cancer is aiming to finalize a buyout of the biotech in the next few weeks, which could be worth about $40 billion or more.
The people said the companies are discussing a price above $200 per share for Cezanne and seeking to seal a deal on or before Merck’s quarterly earnings announcement scheduled for July 28. Seasoned shares closed at $175.13 on Wednesday.